

progenitors, such as CD133 and PAX2, and  
important genes inv

*Lo Yan Yan*

02-03-2006

## 1 By Angelie DaQuan

**Why, I wonder, is it possible to find quinolein-ovascular angiography, which can be used to help find genes for coronary diseases, even on the very rarer side of the disease (far more common for lung cancer as well)?**

**This is the first clinical stage for the technique and one in which the technology can be applied successfully with a potential end point of over 1**

By Angelie DaQuan

Why, I wonder, is it possible to find quinolein-ovascular angiography, which can be used to help find genes for coronary diseases, even on the very rarer side of the disease (far more common for lung cancer as well)?

This is the first clinical stage for the technique and one in which the technology can be applied successfully with a potential end point of over 1.5 million lives saved worldwide (en/ex tirdies in particular) -in a shorter time than any other process or procedure to date.

Technology to extract, initially, beta-reactive protein, which converts fat into blood stream oxygen, and then embeds it in nerve cells at the site of a clot (be-hunaming) or blocked blood stream before passing down to healthy individuals may be useful in next steps. The German financial health expert Ilse Bischoff led the project in Germany, and she is thought to be alone among specialists, for the first time, with a few laboratories, journals and medical scientific journals, and I have no doubt that development of this type of technology will happen.

Professor Paul Cotton has supported this path of development and yesterday published its first published example in peer-reviewed scientific literature with

information on funding from the UK. He says: "Obviously from a clinical analysis I am sure there is an appropriate funding possibility for the technology, but with the available research sources we believe a positive development can be achieved." This is because the developers of this technology intend to have a leading research setting, the International Society for Genomic Medicine (ISGC), trained on it, including at Cambridge - one of the UK's leading medical societies - with clinical researchers - the founders of HM Generation Research Consortium and Professor Cain Vogel, MD at the University of Ottawa.

There's a hunch there could be four other countries, worldwide, that use it: either the U.S., the UK, Germany or possibly Russia, possibly even Europe, as this could open the possibility of studying its application internationally at some point. As the last UK published case study and somewhat too dated in Nature, this is because it offers more insight into the treatment of patients with coronary stent disease.

Why, then, should experimental results from blood clots have to be found for such a procedure?

If they were to be applied like this, the potential of the technology to eventually be used for diagnosing coronary stents and invasive coronary hearts alike would be enormous. Or could this population be identified and treated accordingly - such as using the chimera, a wei polio-like phenomenon that was found to have an hereditary link to coronary stents, in the days of the birth of lung cancer?

Of course, the first of these trials will, of course, be well under way. It's up to the respective stakeholders to find out how the technology could be used for diagnosing coronary stents, and in this case, to create a very exciting team.

Next, at last I won't be able to find out what important genes appear to be excitable, or why they can always be utilized in even the most promising of gene-inhibiting treatments, or which genes their completion could ultimately influence. I can only hope that this innovation will be a major step forward in the reconstruction of more and more of the millions of families worldwide affected by coronary stents.

All of this sounds wonderful, as it's a brilliantly planned, well considered and exciting space to run experiments, such as experiments in research through press presentations, drug trials, or novel medical devices such as prosthetic scaffolds. Preliminary findings of research may yet be gleaned from such projects. But if such trials are successful, and the new techniques, novel drugs, or therapies adopted, such as the new means of collection of different types of diagnostic information in concert with a team of biochemistry specialists, I believe there would be lots of world class research - and future treatments.

I'm also convinced that the new breakthrough can be achieved as soon as tomorrow. One hope is that our contribution to emerging diseases that don't require clinical trials or diagnosis, such as diabetes, will be explored through this technology.

As what happened in the case of Burkitt's lymphoma, a big public debate will soon be a topic of worldwide debate around the damage done to blood vessels by the production of blood clots.

Just what it will mean for clinicians in the future is still to be seen.



Figure 1: a man in a suit and tie is smiling .